Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Abstract

Peptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy-resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A*2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated in a phase I clinical trial of patients with advanced gastric cancer who were refractory to chemotherapy. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluation committee and kept from both patients and investigators until completion of the study. The primary end-point was safety of the peptide vaccination. The secondary end-points were immunological responses and clinical outcome, which were compared between the HLA-A*2402-positive and HLA-A*2402-negative groups. The peptides were subcutaneously administered on day 1, 8, 15 and 22 within a 28-day treatment cycle. A total of 14 patients was enrolled in this study; 12 of the 14 patients received 4 or more vaccinations (at least 1 course). No patient had a severe treatment-related adverse event. Findings from evaluation of clinical responses after a single course showed that 4 cases had stable disease and 8 cases had progressive disease. The median overall survival time (MST) for the 12 patients was 3.9 months. The MSTs in the HLA-A*2402-positive and HLA-A*2402-negative groups were, 4.2 and 3.6 months (p= 0.9164), respectively. The results of this study showed that vaccination with URLC10 and VEGFR1 peptides was a safe treatment for advanced gastric cancer. This trial was registered with University Hospital Medical Information Network (UMIN, no. 000002409).

Low‐dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer

“…The breaking of immune tolerance against tumor‐associated antigens and induction of autoimmunity against tumors should be a useful approach for the treatment of tumors . Although it is common to consider conventional cytotoxic chemotherapy as an immunosuppressive modality, more recent studies have indicated that some cytotoxic drugs have the ability to disrupt pathways of immune suppression and immune tolerance in a manner that depends on the drug type, its dose, and the treatment schedule in relation to the immune‐based intervention .…”

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

“…Feasibility studies evaluated vaccination with tumor-specific antigens in gastric cancer patients (123,124). Vaccination was well-tolerated and showed an increase in antitumor immuno-response.…”

Vaccination with a Paramyosin-Based Multi-Epitope Vaccine Elicits Significant Protective Immunity against Trichinella spiralis Infection in Mice

“…Compared to whole-protein antigens, an epitope-based vaccine may overcome these above-mentioned shortcomings and have many advantages such as increased safety and immunogenicity of vaccine for increased protective potency ( Tang et al, 2015 ). The epitope-based vaccines are on the road to the market, especially in the treatment of cancer ( Higashihara et al, 2014 ; Correale et al, 2016 ).…”